KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Income from Continuing Operations (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Income from Continuing Operations for 6 consecutive years, with 108122000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 39.56% year-over-year to 108122000.0, compared with a TTM value of 644759000.0 through Dec 2025, down 39.06%, and an annual FY2025 reading of 644759000.0, down 39.06% over the prior year.
  • Income from Continuing Operations was 108122000.0 for Q4 2025 at Recursion Pharmaceuticals, up from 162253000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 30484000.0 in Q1 2021 and bottomed at 202487000.0 in Q1 2025.
  • Average Income from Continuing Operations over 5 years is 93249400.0, with a median of 84049500.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations tumbled 153.94% in 2021, then soared 39.56% in 2025.
  • Year by year, Income from Continuing Operations stood at 64960000.0 in 2021, then increased by 6.12% to 60982000.0 in 2022, then tumbled by 52.5% to 92996000.0 in 2023, then tumbled by 92.38% to 178906000.0 in 2024, then soared by 39.56% to 108122000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for RXRX at 108122000.0 in Q4 2025, 162253000.0 in Q3 2025, and 171897000.0 in Q2 2025.